Need assistance?
We’re here for you

Need assistance?
We’re here for you

NovoCare® is here to help patients like you access and afford their medications.

This site is available 24/7, and we offer live support through the phone numbers listed below. Further down on this page you’ll also find answers to frequently asked questions.

Diabetes 

844‑Novo4Me (844‑668‑6463)

Monday-Friday, 8:00 am-11:00 pm
Saturday, 11:00 am-7:00 pm
Eastern Standard Time

Obesity

888-809-3942

Monday-Friday, 8:00 am-8:00 pm
Eastern Standard Time

Growth Hormone 

888-668-6444

Monday-Friday, 8:00 am-8:00 pm
Eastern Standard Time

Hemophilia 

844-668-6732

Monday-Friday, 8:00 am-8:00 pm
Eastern Standard Time


Report a side effect or issue with your medication

Please submit a form online or by calling 800‑727‑6500


Frequently Asked Questions 

Medicines are incredibly expensive to research and develop in general. It can take billions of dollars to bring a single safe and effective medicine to market.

Your insurance situation also factors into the price you pay for medicine. Novo Nordisk has teams of people negotiating with insurers to ensure better coverage for our products. Ultimately, though, it’s up to the insurer to decide whether to cover a product and the level of coverage. Additionally, your insurance provider will determine whether you pay a flat fee, called a “copay” or a percentage of the total cost, called “co-insurance."

To find out if your insurance covers your medicine, make a selection below.

Diabetes medicines
Fiasp® (insulin aspart injection) 100 U/mL
Levemir® (insulin detemir injection) 100 U/mL
NovoLog® (insulin aspart) injection 100 U/mL
NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart) injectable suspension 100 U/mL
Ozempic® (semaglutide) injection 0.5 mg or 1 mg
RYBELSUS® (semaglutide) tablets 3 mg, 7 mg, or 14 mg
Tresiba® (insulin degludec injection) 100 U/mL or 200 U/mL
Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 U/mL and 3.6 mg/mL

Obesity medicines
Saxenda® (liraglutide) injection 3 mg
Wegovy® (semaglutide) injection 2.4 mg

Growth-related disorders medicines
For coverage information about Novo Nordisk growth-related disorders medicines, connect with a NovoCare® representative at 888-668-6444

Hemophilia and rare bleeding disorders medicines
For coverage information about Novo Nordisk hemophilia and rare bleeding disorders medicines, connect with a NovoCare® representative at 844-668-6732

There are limits to the ways in which Novo Nordisk can support patients with government-funded insurance.  

For patients with diabetes, please call 844-Novo4Me (844-668-6463) to discuss other options that may be available.

For patients with obesity, growth-related disorders or hemophilia and bleeding disorders, please contact your prescription insurance provider to discuss options.

We have assistance programs and savings offers which may help reduce the cost of your insulin or provide it at no cost, depending on your situation.

If you have questions about your copay card, please contact the following numbers for your medicine:

Diabetes medicines
Fiasp®—877-304-6855
NovoLog®—877-304-6855
NovoLog® Mix 70/30—877-304-6855
Ozempic®—877-304-6855
RYBELSUS®—877-304-6855
Tresiba®—833-992-3299

Obesity medicines
Saxenda®—877-304-6895
Wegovy®—888-793-1218

Growth-related disorders medicines
Norditropin® (somatropin) injection 5 mg, 10 mg, 15 mg, 30 mg pens—866-316-2404
Macrilen™ (macimorelin) 60 mg for oral solution—888-668-6444

Hemophilia and rare bleeding disorders medicines
For all hemophilia and rare bleeding disorder medications, please call 844-668-6732

Disclaimer   
Privacy Policy   
Cookie Policy   
Contact Us   
Novo Nordisk US

Novo Nordisk logo

FlexPen®, FlexTouch®, Levemir®, NovoCare®, NovoFine®, NovoTwist®, Victoza®, Xultophy®, and Wegovy® are registered trademarks of Novo Nordisk A/S. 
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

© 2022 Novo Nordisk  All rights reserved. US21NC00007 February 2022